Two-year clinical outcome from the Iberian registry patients after left atrial appendage closure

Heart

Volumn 101, Issue 11, 2015, Pages 877-883

  Mínguez, José Ramón López ^a   Asensio, Juan Manuel Nogales ^a   Gragera, Javier Elduayen ^a   Costa, Marco ^b   González, Ignacio Cruz ^c   De Carlos, Federico Gimeno ^d   Díaz, José Antonio Fernández ^e   Yuste, Victoria Martín ^f   González, Raúl Moreno ^g   Domínguez Franco, Antonio ^h   Buendía, Amparo Benedicto ⁱ   Garibi, Jesús Herrero ^j   Hernández, Felipe Hernández ^k   Ribeiro, Vasco Gama ^l  

^a HOSPITAL INFANTA CRISTINA   (Spain)

^b Diabetes and Growth Department   (Portugal)

^c HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^e HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^f HOSPITAL CLÍNIC   (Spain)

^g HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^h HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

ⁱ HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^j HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^k HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^l Hospital de Oporto   (Portugal)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CEPHALOSPORIN; CLOPIDOGREL;

AGE; AGED; ANAMNESIS; ARTICLE; ATRIAL FIBRILLATION; BRAIN HEMATOMA; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE PREDISPOSITION; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GENDER; HEART ATRIUM APPENDAGE; HEART ATRIUM SEPTUM DEFECT; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; KIDNEY FUNCTION; LEFT ATRIAL APPENDAGE CLOSURE DEVICE; LIVER FUNCTION; LOADING DRUG DOSE; LOWER GASTROINTESTINAL BLEEDING; MAJOR CLINICAL STUDY; MALE; NON VALVULAR ATRIAL FIBRILLATION; OUTCOME ASSESSMENT; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; THROMBOEMBOLISM; THROMBUS; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; TREATMENT INDICATION; UPPER GASTROINTESTINAL BLEEDING; VERY ELDERLY; ADVERSE EFFECTS; ARTIFICIAL EMBOLISM; CLINICAL TRIAL; EVALUATION STUDY; GASTROINTESTINAL DISEASES; HEART ATRIUM; HEMORRHAGE; MULTICENTER STUDY; PROCEDURES; PROSTHESIS; PROSTHESIS IMPLANTATION; REGISTER; SEPTAL OCCLUDER; STROKE; TREATMENT OUTCOME;

AGED; ATRIAL APPENDAGE; ATRIAL FIBRILLATION; FEMALE; GASTROINTESTINAL DISEASES; HEART ATRIA; HEMORRHAGE; HUMANS; MALE; PROSTHESIS DESIGN; PROSTHESIS IMPLANTATION; REGISTRIES; SEPTAL OCCLUDER DEVICE; STROKE; THERAPEUTIC OCCLUSION; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 84930657279     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2014-306332     Document Type: Article

References (30)

1. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955-62.
2. Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 2009;374:534-42.
3. Reddy VY, Doshi SK, Sievert H, et al. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial. Circulation 2013;127:720-9.
4. Gangireddy SR, Halperin JL, Fuster V, et al. Percutaneous left atrial appendage closure for stroke prevention in patients with atrial fi brillation: an assessment of net clinical bene fit. Eur Heart J 2012;33:2700-8.
5. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33:2719-47.
6. Gage BF, van Walraven C, Pearce L, et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 2004;110:2287-92.
7. Coppens M, Eikelboom JW, Hart RG, et al. The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to bene fit from oral anticoagulant therapy. Eur Heart J 2013;34:170-6.
8. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010;138:1093-100.
9. Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J 2012;33:1500-10.
10. Schulman S, Angeras U, Bergqvist D, et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 2010;8:202-4.
11. Leon MB, Piazza N, Nikolsky E, et al. Standardized endpoint definitions for Transcatheter Aortic Valve Implantation clinical trials: a consensus report from the Valve Academic Research Consortium. J Am Coll Cardiol 2011;57:253-69.
12. Park JW, Bethencourt A, Sievert H, et al. Left atrial appendage closure with Amplatzer cardiac plug in atrial fibrillation: initial European experience. Catheter Cardiovasc Interv 2011;77:700-6.
13. Reddy VY, Mobius-Winkler S, Miller MA, et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). J Am Coll Cardiol 2013;61:2551-6.
14. Lopez-Minguez JR, Eldoayen-Gragera J, Gonzalez-Fernandez R, et al. Immediate and one-year results in 35 consecutive patients after closure of left atrial appendage with the Amplatzer cardiac plug. Rev Esp Cardiol 2013;66:90-7.
15. Urena M, Rodes-Cabau J, Freixa X, et al. Percutaneous left atrial appendage closure with the AMPLATZER cardiac plug device in patients with nonvalvular atrial fibrillation and contraindications to anticoagulation therapy. J Am Coll Cardiol 2013;62:96-102.
16. Meincke F, Schmidt-Salzmann M, Kreidel F, et al . New technical and anticoagulation aspects for left atrial appendage closure using the WATCHMAN(R) device in patients not taking warfarin. EuroIntervention 2013;9:463-8.
17. Nietlispach F, Gloekler S, Krause R, et al. Amplatzer left atrial appendage occlusion: single center 10-year experience. Catheter Cardiovasc Interv 2013;82:283-9.
18. Chun KR, Bordignon S, Urban V, et al. Left atrial appendage closure followed by 6 weeks of antithrombotic therapy: a prospective single-center experience. Heart Rhythm 2013;10:1792-9.
19. Plicht B, Konorza TF, Kahlert P, et al. Risk factors for thrombus formation on the Amplatzer cardiac plug after left atrial appendage occlusion. JACC Cardiovasc Interv 2013;6:606-13.
20. Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007;370:493-503.
21. Connolly SJ, Pogue J, Hart RG, et al. Effect of clopidogrel added to aspirin in patients with atrial fi brillation. N Engl J Med 2009;360:2066-78.
22. Deitelzweig SB, Pinsky B, Buysman E, et al. Bleeding as an outcome among patients with nonvalvular atrial fibrillation in a large managed care population. Clin Ther 2013;35:1536-45 e1.
23. Deitelzweig SB, Buysman E, Pinsky B, et al. Warfarin use and stroke risk among patients with nonvalvular atrial fibrillation in a large managed care population. Clin Ther 2013;35:1201-10.
24. Patel MR, Hellkamp AS, Lokhnygina Y, et al. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). J Am Coll Cardiol 2013;61:651-8.
25. Pengo V, Legnani C, Noventa F, et al. Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding. A Multicenter Inception Cohort Study. Thromb Haemost 2001;85:418-22.
26. Levi M, Hovingh K. Bleeding complications in patients on anticoagulants who would have been disquali fied for clinical trials. Thromb Haemost 2008;100:1047-51.
27. Majeed A, Hwang HG, Connolly SJ, et al. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation 2013;128:2325-32.
28. Witt DM, Delate T, Garcia DA, et al. Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding. Arch Intern Med 2012;172:1484-91.
29. Reddy VY, Holmes D, Doshi SK, et al. Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry. Circulation 2011;123:417-24.
30. Park JW, Sievert H, Schillinger W, et al. Interim data from AMPLATZER cardiac plug registry [Abstract]. J Am Coll Cardiol 2011;58:Abstract TCT-112.